Quest Diagnostics Incorporated (DGX)
NYSE · Healthcare · Diagnostics & Research
Quest Diagnostics Incorporated is a Healthcare company with a market capitalization of $23.23B, a trailing P/E ratio of 23.2, and a dividend yield of 1.58%.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | April 21, 2026 | $2.50 | $2.37 | +5.5% |
| Q4 2025 | February 10, 2026 | $2.42 | $2.36 | +2.5% |
| Q3 2025 | October 21, 2025 | $2.60 | $2.50 | +4.0% |
| Q2 2025 | July 22, 2025 | $2.62 | $2.57 | +1.9% |
| Q1 2025 | April 22, 2025 | $2.21 | $2.15 | +2.8% |
| Q4 2024 | January 30, 2025 | $2.23 | $2.18 | +2.3% |
Other Diagnostics & Research Stocks
Frequently Asked Questions
What is Quest Diagnostics Incorporated's market cap?
As of June 29, 2026, Quest Diagnostics Incorporated (DGX) has a market capitalization of $23.23B.
What is Quest Diagnostics Incorporated's P/E ratio?
Quest Diagnostics Incorporated trades at a trailing price-to-earnings (P/E) ratio of 23.2. Its forward P/E is 19.2.
Does Quest Diagnostics Incorporated pay a dividend?
Yes — Quest Diagnostics Incorporated pays a dividend yielding 1.58%, an annual payout of $3.26 per share.
What sector is DGX in?
Quest Diagnostics Incorporated is in the Healthcare sector, specifically the Diagnostics & Research industry.
What was Quest Diagnostics Incorporated's revenue?
In its latest reported fiscal year (ending December 31, 2025), Quest Diagnostics Incorporated reported revenue of $11.04B and net income of $992.00M.
Ask your own questions about DGX
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.